SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 9, 2021

 

 

INTERNATIONAL STEM CELL CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-51891

 

20-4494098

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification
Number)

 

5950 Priestly Drive, Carlsbad, California 92008

(Address of principal executive offices, including zip code)

(760) 940-6383

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

None

 

N/A

 

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders

International Stem Cell Corporation (the “Company”) held its Annual Meeting of Stockholders on June 9, 2021. The stockholders considered one proposal, which is described in more detail in the Company’s definitive proxy statement dated April 29, 2021.

Proposal 1:

  

Election of four directors to hold office until the 2022 Annual Meeting:

  

A.

Directors elected by holders of Series D Preferred Stock:

 

 

Votes For

 

Votes Withheld

Andrey Semechkin

 

2,457,143

 

—

Russell Kern

 

2,457,143

 

—

  

B.

Directors elected by holders of all shares of stock (including shares of preferred stock voting on an as-converted basis):

 

 

Votes For

 

Votes Withheld

Donald A. Wright

 

7,524,706

 

47,516

Paul V. Maier

 

7,523,681

 

48,541

Broker Non-Votes: none

All of the foregoing candidates were elected.

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

INTERNATIONAL STEM CELL CORPORATION

 

 

 

 

Date: June 14, 2021

 

 

 

By:

 

/s/ Sophia Garnette

 

 

 

 

 

 

Sophia Garnette

 

 

 

 

 

 

VP Legal Affairs and Operations

 

 

International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more International Stem Cell (QB) Charts.
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more International Stem Cell (QB) Charts.